patients are at the beginning, middle, and heart of all we do. harmony biosciences, llc, is a privately-owned biopharmaceutical company. the company was established in october 2017 with a vision to provide novel treatment options for people living with rare and orphan diseases with an emphasis on central nervous system disorders, starting with a focus on helping patients who live with narcolepsy. harmony biosciences is committed to advancing the understanding of narcolepsy and providing information and resources to individuals who live with, and healthcare professionals who treat, patients with narcolepsy.
Company profile
Ticker
HRMY
Exchange
Website
CEO
John C. Jacobs
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
Subsidiaries
Harmony Biosciences, LLC • Zynerba Pharmaceuticals, Inc. • Zynerba Pharmaceuticals Pty Ltd ...
IRS number
822279923
HRMY stock data
Latest filings (excl ownership)
ARS
2023 FY
Annual report to shareholders
11 Apr 24
8-K
Entry into a Material Definitive Agreement
11 Apr 24
DEFA14A
Additional proxy soliciting materials
11 Apr 24
DEF 14A
Definitive proxy
11 Apr 24
10-K/A
2023 FY
Annual report (amended)
28 Feb 24
S-8
Registration of securities for employees
22 Feb 24
10-K
2023 FY
Annual report
22 Feb 24
8-K
Harmony Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates
22 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
8-K/A
Consolidated Financial Statements
7 Dec 23
Transcripts
HRMY
Earnings call transcript
2023 Q4
22 Feb 24
HRMY
Earnings call transcript
2023 Q3
31 Oct 23
HRMY
Earnings call transcript
2023 Q2
1 Aug 23
HRMY
Earnings call transcript
2023 Q1
2 May 23
HRMY
Earnings call transcript
2022 Q4
21 Feb 23
HRMY
Earnings call transcript
2022 Q3
1 Nov 22
HRMY
Earnings call transcript
2022 Q2
2 Aug 22
HRMY
Earnings call transcript
2022 Q1
3 May 22
HRMY
Earnings call transcript
2021 Q4
28 Feb 22
HRMY
Earnings call transcript
2021 Q3
14 Nov 21
Latest ownership filings
4
Sandip Kapadia
2 Apr 24
4
Jeffrey Dierks
18 Mar 24
144
Notice of proposed sale of securities
15 Mar 24
4
Jeffrey Dierks
11 Mar 24
144
Notice of proposed sale of securities
8 Mar 24
SC 13G/A
Valor IV Pharma Holdings, LLC
13 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
FMR LLC
9 Feb 24
4
Kumar Budur
26 Jan 24
3
Kumar Budur
26 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 204 |
Opened positions | 32 |
Closed positions | 37 |
Increased positions | 84 |
Reduced positions | 55 |
13F shares | Current |
---|---|
Total value | 1.61 tn |
Total shares | 78.54 mm |
Total puts | 106.20 k |
Total calls | 292.90 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Valor IV Pharma | 11.22 mm | $0.00 |
Valor Management | 11.22 mm | $367.61 bn |
Fund Trust Marshman II | 10.65 mm | $385.04 mm |
BLK Blackrock | 6.13 mm | $200.96 bn |
FMR | 5.45 mm | $178.60 bn |
Vanguard | 3.68 mm | $120.73 bn |
venBio Global Strategic Fund II | 2.74 mm | $0.00 |
Vivo Capital | 2.61 mm | $85.41 bn |
Vivo Capital VIII | 2.57 mm | $0.00 |
HBM Healthcare Investments | 2.15 mm | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Mar 24 | Sandip Kapadia | Common Stock | Payment of exercise | Dispose F | No | No | 33.58 | 8,013 | 269.08 k | 6,987 |
29 Mar 24 | Sandip Kapadia | Common Stock | Option exercise | Acquire M | No | No | 0 | 15,000 | 0.00 | 15,000 |
29 Mar 24 | Sandip Kapadia | RSU Common Stock | Option exercise | Dispose M | No | No | 0 | 15,000 | 0.00 | 15,000 |
15 Mar 24 | Jeffrey Dierks | Common Stock | Sell | Dispose S | No | Yes | 32 | 11,979 | 383.33 k | 0 |
15 Mar 24 | Jeffrey Dierks | Common Stock | Option exercise | Acquire M | No | No | 8.22 | 11,979 | 98.47 k | 11,979 |
15 Mar 24 | Jeffrey Dierks | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.22 | 9,644 | 79.27 k | 4,869 |
15 Mar 24 | Jeffrey Dierks | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.22 | 2,335 | 19.19 k | 0 |
8 Mar 24 | Jeffrey Dierks | Common Stock | Sell | Dispose S | No | Yes | 32 | 194 | 6.21 k | 0 |
8 Mar 24 | Jeffrey Dierks | Common Stock | Option exercise | Acquire M | No | No | 8.22 | 194 | 1.59 k | 194 |
8 Mar 24 | Jeffrey Dierks | Stock Option Common Stock | Option exercise | Dispose M | No | No | 8.22 | 94 | 772.68 | 14,513 |
News
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
12 Apr 24
Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
11 Apr 24
Harmony Biosciences Announces Exclusive Agreement To Develop And Commercialize TPM-1116, A Highly Potent And Selective Oral Orexin-2 Receptor Agonist; Harmony Will Pay Bioprojet An Upfront License Fee Of $25.5M For The Exclusive Right
11 Apr 24
Needham Reiterates Buy on Harmony Biosciences, Maintains $50 Price Target
9 Apr 24
Cantor Fitzgerald Reiterates Overweight on Harmony Biosciences, Maintains $49 Price Target
28 Mar 24
Press releases
HARMONY BIOSCIENCES TO REPORT FIRST QUARTER 2024 FINANCIAL RESULTS ON APRIL 30, 2024
16 Apr 24
HARMONY BIOSCIENCES ANNOUNCES EXCLUSIVE AGREEMENT TO DEVELOP AND COMMERCIALIZE TPM-1116, A HIGHLY POTENT AND SELECTIVE ORAL OREXIN-2 RECEPTOR AGONIST
11 Apr 24
HARMONY BIOSCIENCES INITIATES GLOBAL PHASE 3 REGISTRATIONAL TRIAL (TEMPO STUDY) OF PITOLISANT IN PATIENTS WITH PRADER-WILLI SYNDROME
3 Apr 24
HARMONY BIOSCIENCES TO PARTICIPATE IN 23RD ANNUAL NEEDHAM VIRTUAL HEALTHCARE CONFERENCE
26 Mar 24
HARMONY BIOSCIENCES TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES
28 Feb 24